Libya is experiencing an ongoing crisis. Social media interactions reveal the suffering of cancer patients. This is due to drug shortages. Shipments are often delayed. Dr. Haidar Al-Sayeh, head of the National Center for Disease Control, addressed these concerns. Citizens are demanding clarification on reasons for delays. They also seek precise delivery schedules.
A citizen recently complained about a delayed cancer drug. Patients are waiting for their vital doses. Previous assurances about availability were not met. Some patients bought their medication abroad. It was unavailable during expected delivery times.
The discussion included questions about the delays’ causes. How are stalled shipments being handled? Were payments made for undelivered drugs? Critics also noted a lack of early patient information. They demanded more transparent official statements on the cancer drug crisis.
Al-Sayeh stated that a required drug shipment was manufactured in July 2025. This was based on supplier correspondence. However, the Central Bank of Libya delayed opening the letter of credit. This delay lasted until January. It prevented the shipment’s timely arrival.
Al-Sayeh explained initial company communications. They indicated the shipment’s imminent arrival. Later, its shelf life was found to be affected. Regulatory bodies then refused to release it. Efforts shifted to manufacturing new drugs. A new arrival schedule was set. This followed official company correspondence.
A circulating schedule details new cancer drug shipments. These include trade names like NOLVADEX, ZOLADEX, TAGRISSO, ARIMIDEX, IMFINZI, and LYNPARZA. Arrival dates range from late April to May and June 2026. For one item, goods are ready for shipment. They await an amendment to the letter of credit. In another response, Al-Sayeh confirmed a specific drug. It was part of previous procurements. These were outside the authority’s scope. He added that the original AstraZeneca drug would be available by month’s end.
This interaction highlights immense pressure on cancer patients. Their treatment requires precise, time-sensitive doses. Delays are unacceptable. This sparked widespread public sympathy. Calls intensified for accelerated drug provision. They also demanded regular supply. Clear data must be provided to the public and patients. This data should detail available and delayed items.